Firms to collaborate on aseptic formulation and filling.

SynCo Bio Partners and Prosensa will collaborate in the formulation and fill of Prosensa’s RNA-based therapeutics for Duchenne muscular dystrophy (DMD).

“SynCo is pleased to be working with Prosensa on this important clinical program for the life-saving treatment of DMD,” Pierre Warffemius, CEO of SynCo commented. “We aim to establish a long-term relationship with Prosensa to support their expanding portfolio of nucleic acid based therapeutics against neuromuscular disorders by providing high quality aseptic formulation and filling services.”

Previous articleThrombogenics Outlicenses Stem Cell Medium Technology to Millipore
Next articleHarvard Med School and Brigham & Women’s Deploy BioTrove Technology